Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Bovine Respiratory Disease Treatment
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.4 Billion by the end ... Read More
-
Anti-Inflammatory Therapeutics
... CAGR of 4.3% over the analysis period 2024-2030. Anti-Inflammatory Biologics, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$67.7 Billion by the end of the analysis ... Read More
-
Guillain-Barre Syndrome Therapeutics
... at a CAGR of 4.7% over the analysis period 2024-2030. Intravenous Immunoglobulin, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$541.2 Million by the end of ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC) Therapeutics, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by ... Read More
-
Fragment-based Drug Discovery
... at a CAGR of 8.8% over the analysis period 2024-2030. Fragment Screening Technology, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.1 Billion by the end ... Read More
-
Glaucoma Therapeutics
... CAGR of 3.5% over the analysis period 2024-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.9 Billion by the end of the analysis ... Read More
-
Uterine Cancer Therapeutics and Diagnostics
... Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Endometrial Carcinomas Therapeutics & Diagnostics, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and ... Read More
-
Vitiligo Therapeutics
... CAGR of 4.0% over the analysis period 2024-2030. Topical Therapeutics, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.2 Billion by the end of the analysis ... Read More
-
Dilated Cardiomyopathy Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Angiotensin II Receptor Blockers (ARBs), one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$258.2 Million by ... Read More
-
Alpha 1 Antitrypsin Deficiency Treatment
... Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Augmentation Therapy, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$2.0 Billion ... Read More
-
Infertility Drugs
... CAGR of 5.2% over the analysis period 2024-2030. Hormone-Based Therapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$5.3 Billion by the end of the analysis ... Read More
-
Skin Allergy Therapeutics
... at a CAGR of 5.3% over the analysis period 2024-2030. The U.S. Market is Estimated at US$492.4 Million While China is Forecast to Grow at 8.3% CAGR The Skin Allergy Therapeutics market in the U.S. ... Read More
-
Liver Diseases Treatment
... at a CAGR of 10.5% over the analysis period 2024-2030. Anti-Rejection Drugs/Immunosupressants, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$6.3 Billion by the end of ... Read More
-
Scleroderma Diagnostics and Therapeutics
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Localized Disease, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$1.9 Billion by the ... Read More
-
Influenza Medication
... CAGR of 1.9% over the analysis period 2024-2030. Zanamivir, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$123.9 Million by the end of the analysis period. ... Read More
-
Rheumatology Therapeutics
... CAGR of 3.2% over the analysis period 2024-2030. Disease Modifying Anti-Rheumatic Drugs (DMARDs), one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$51.3 Billion by the end ... Read More
-
Drug Discovery Services
... at a CAGR of 1.8% over the analysis period 2024-2030. Medicinal Chemistry Services, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$31.6 Billion by the end ... Read More
-
Hunter Syndrome Treatment
... at a CAGR of 5.7% over the analysis period 2024-2030. Enzyme Replacement Therapy (ERT), one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$1.4 Billion by the ... Read More
-
Male Infertility
... CAGR of 5.9% over the analysis period 2024-2030. DNA Fragmentation Technique, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Gastroesophageal Reflux Disease (GERD) Therapeutics
... Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Antacids, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$3.6 Billion by ... Read More
-
Myelodysplastic Syndrome (MDS) Drugs
... 2030, growing at a CAGR of 9.3% over the analysis period 2024-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$2.7 Billion by the ... Read More
-
Rapid Application Development
... at a CAGR of 37.6% over the analysis period 2024-2030. Rapid Application Development Tools, one of the segments analyzed in the report, is expected to record a 36.1% CAGR and reach US$465.3 Billion by the ... Read More
-
Myasthenia Gravis Treatment
... at a CAGR of 6.3% over the analysis period 2024-2030. Medication Treatment, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.2 Billion by the end of ... Read More
-
Radiodermatitis
... 4.2% over the analysis period 2024-2030. Topical Products, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$412.0 Million by the end of the analysis period. Growth ... Read More
-
Bioconjugation Market by Product (Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D) - Global Forecast to 2029
... of the bioconjugation market. The development of targeted therapeutics such as ADCs is expected to be greatly supported by bioconjugation, as the need for more accurate and potent cancer treatments grows. Furthermore, there is a ... Read More
Research Assistance
